Skip to main content
Elsevier
View Cart

Coronaviruses and other Novel Antiviral Targets

  • 1st Edition, Volume 57 - November 17, 2021
  • Latest edition
  • Editor: Katherine Seley-Radtke
  • Language: English

Annual Reports in Medicinal Chemistry, Volume 57 in this long-running series, highlights new advances in the field with this new volume presenting interesting chapters on the Mecha… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Explore resources

Description

Annual Reports in Medicinal Chemistry, Volume 57 in this long-running series, highlights new advances in the field with this new volume presenting interesting chapters on the Mechanism of action of the broadly acting antiviral drug remdesivir, Improving properties of the nucleobase analogue T-706 as a potential anti-SARS-CoV-2 and anti-influenza compound, Antivirals for RNA virus infections Anno 2020-2021, Broad spectrum antiviral fleximer nucleosides, SARS-CoV-2 main protease inhibitors, The search for antivirals to treat alphavirus infections, Inhibitors of Ebola Virus targeting Innate immune evasion, Uracil derivatives as non-nucleoside inhibitors of viral infections, and more.

Key features

  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in the Annual Reports in Medicinal Chemistry
  • Updated release includes the latest information on the Coronaviruses and other novel antiviral targets

Readership

Undergraduates, graduates, academics, and researchers in the field of medicinal chemistry

Table of contents

1. Improving properties of the nucleobase analogs T-705/T-1105 as potential antivirals

Chris Meier

2. Anno 2021: Which antivirals for the coming decade?

Piet Herdewijn and Eric De Clercq

3. Broad spectrum antiviral fleximer nucleosides

Katherine L. Seley-Radtke, Joy E. Thames and Charles D. Waters III

4. The search for antivirals to treat alphavirus infections

Andrea Brancale and Marcella Bassetto

5. Inhibitors of Ebola Virus targeting Innate immune evasion

Enzo Tramontano, Angela Corona and Anna Laura Paulis

6. Uracil derivatives as non-nucleoside inhibitors of viral infections

Anastasia Khandazhinskaya

Product details

  • Edition: 1
  • Latest edition
  • Volume: 57
  • Published: November 17, 2021
  • Language: English

About the editor

KS

Katherine Seley-Radtke

Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as the Program Director for UMBC’s Chemistry-Biology Interface graduate training program funded by NIH since 2007. This program promotes hands on cross disciplinary research for almost 50 PhD students from four departments at UMBC and UMB. She is currently the Immediate Past President and Secretary-Elect for the International Society of Nucleosides, Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy, Molecules – Chemical Biology, and Current Protocols in Chemical Biology.
Affiliations and expertise
Professor of Chemistry and Biochemistry, University of Maryland, Baltimore County, MD, USA

View book on ScienceDirect

Read Coronaviruses and other Novel Antiviral Targets on ScienceDirect